A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis

Sponsor
European Myeloma Network B.V.
Study ID
NCT06649695
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • AL Amyloidosis

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Teclistamab — DRUG
    Teclistamab will be administered via a subcutaneous injection (SC)

Study Details

This is a multicenter open-label, phase 2 study in participant with previously treated immunoglobulin light-chain (AL) Amyloidosis to evaluate the benefit of teclistamab

Key Dates

Start date
Jul 2, 2025
Status verified
Mar 2026
Primary completion
Sep 30, 2028
Completion
Sep 30, 2028

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Teclistamab
    Teclistamab will be administered via a subcutaneous injection (SC)

Primary Outcome Measure

Hematologic Complete Response (CR) rate [ Time Frame: baseline up to 3 cycles of treatment (approximately 3 months) ]

Central Contacts

Related Studies